DE602007013385D1 - Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung - Google Patents

Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung

Info

Publication number
DE602007013385D1
DE602007013385D1 DE602007013385T DE602007013385T DE602007013385D1 DE 602007013385 D1 DE602007013385 D1 DE 602007013385D1 DE 602007013385 T DE602007013385 T DE 602007013385T DE 602007013385 T DE602007013385 T DE 602007013385T DE 602007013385 D1 DE602007013385 D1 DE 602007013385D1
Authority
DE
Germany
Prior art keywords
glp
diseases
spherical
conditions associated
pharmacic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013385T
Other languages
English (en)
Inventor
Peter Geigle
Christine Wallrapp
Eric Thoenes
Frank Thuermer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocompatibles UK Ltd
Original Assignee
Biocompatibles UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles UK Ltd filed Critical Biocompatibles UK Ltd
Publication of DE602007013385D1 publication Critical patent/DE602007013385D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
DE602007013385T 2006-05-10 2007-04-27 Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung Active DE602007013385D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06009678A EP1854455B1 (de) 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
PCT/EP2007/003775 WO2007128443A2 (en) 2006-05-10 2007-04-27 Spherical or non-spherical microcapsules comprising glp-i peptides, their production and use

Publications (1)

Publication Number Publication Date
DE602007013385D1 true DE602007013385D1 (de) 2011-05-05

Family

ID=37773605

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006009631T Expired - Fee Related DE602006009631D1 (de) 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
DE602007013385T Active DE602007013385D1 (de) 2006-05-10 2007-04-27 Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006009631T Expired - Fee Related DE602006009631D1 (de) 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung

Country Status (13)

Country Link
US (2) US8790705B2 (de)
EP (3) EP1854455B1 (de)
JP (1) JP5209608B2 (de)
CN (1) CN101489539A (de)
AT (2) ATE444741T1 (de)
AU (1) AU2007247511B2 (de)
CA (1) CA2649902A1 (de)
DE (2) DE602006009631D1 (de)
DK (1) DK2015736T3 (de)
ES (1) ES2363810T3 (de)
PL (1) PL2015736T3 (de)
PT (1) PT2015736E (de)
WO (1) WO2007128443A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1767545E (pt) 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2176400B1 (de) * 2007-07-11 2015-10-14 Technion Research & Development Foundation Ltd. Verkapselte mesenchymale stammzellen und verwendungen davon
EP2163243A1 (de) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
EP2251028A1 (de) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren
US20120020931A1 (en) 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
WO2012034704A1 (en) * 2010-09-15 2012-03-22 Biocompatibles Uk Ltd. Treatment of vascular diseases using encapsulated cells encoding and secreting glp-1, or a fragment or variant thereof
CN108392263A (zh) 2011-01-19 2018-08-14 弗拉克泰尔实验室公司 用于组织处理的装置与方法
SG193615A1 (en) * 2011-03-29 2013-11-29 Beta Cell Nv Method for encapsulated therapeutic products and uses thereof
US9388385B2 (en) * 2011-05-19 2016-07-12 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
KR101335176B1 (ko) * 2011-12-12 2013-11-29 테고사이언스 (주) 상처 치유용 드레싱재제
KR102245697B1 (ko) 2012-02-27 2021-04-28 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
EP4218884A3 (de) 2012-04-19 2023-09-13 Fractyl Health, Inc. Gewebeexpansionsvorrichtungen, -systeme und -verfahren
WO2014022436A1 (en) 2012-07-30 2014-02-06 Fractyl Laboratories Inc. Electrical energy ablation systems, devices and methods for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
EP3071286B1 (de) * 2013-11-22 2024-01-03 Fractyl Health, Inc. Systeme zur erzeugung einer therapeutischen einschränkung im magen-darm-trakt
CN104805058A (zh) * 2014-01-23 2015-07-29 上海欧易生物医学科技有限公司 一种稳定表达外源性glp-1基因的人脐带源间充质干细胞株
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
WO2016011269A1 (en) 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
EA201891469A1 (ru) 2015-12-23 2018-12-28 Дзе Джонс Хопкинс Юниверсити Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
WO2019119673A1 (zh) * 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN111803617A (zh) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 一种内载微囊的干细胞系统与制备方法
US20220389071A9 (en) * 2020-09-22 2022-12-08 Yang Wei Long-lasting glp1 analogue drug for type-2 diabetes
CN113493764B (zh) * 2021-07-27 2023-01-24 新乡医学院 一种体外诱导小鼠耳朵间充质干细胞分化为脂肪细胞的方法
WO2023028554A1 (en) * 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
EP0499990B1 (de) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von cysteinfreien Peptiden
GB9311147D0 (en) 1993-05-28 1993-07-14 Long Ashton Research Station Regulation of plant growth
ATE505485T1 (de) 1996-03-01 2011-04-15 Novo Nordisk As Appetithemmendes peptid, zusammensetzung und verwendung
CA2262647C (en) * 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
AU4863797A (en) 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
EP1045898A2 (de) 1998-01-12 2000-10-25 Betagene, Inc. Zusammensetzungen und verfahren für die regulierung der expression aus neuroendocrinezellinien
EP1062229A1 (de) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmakologisch aktive peptid-konjugate mit verringerter neigung enzymatisch hydrolysiert zu werden
WO1999053064A2 (en) * 1998-04-13 1999-10-21 Modex Therapeutiques, S.A. Methods of delivering glp-1
DE19836960A1 (de) 1998-08-14 2000-02-17 Ulrich Zimmermann Verfahren zur Gewinnung hochgereinigter Alginate
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
DE19904785A1 (de) 1999-02-05 2000-08-10 Ulrich Zimmermann Verfahren zur Herstellung von stabilem Alginatmaterial
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
AU2002226897B2 (en) 2000-12-07 2007-10-25 Eli Lilly And Company GLP-1 fusion proteins
AU2002240463A1 (en) 2001-02-22 2002-09-12 Novartis Ag Use of endostatin in the treatment of ocular neovascularization
ES2298378T3 (es) * 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
WO2003010305A1 (en) 2001-07-27 2003-02-06 Arhus Amt Immortilized stem cells
EP2275117B1 (de) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
EP1790353A1 (de) * 2001-12-29 2007-05-30 Novo Nordisk A/S Kombinierte Verwendung einer GLP-1-Verbidnung und eines Modulators für Spätfolgen bei Diabetes
AR038102A1 (es) 2002-01-08 2004-12-29 Lilly Co Eli Analogos extendidos de peptido 1 de tipo glucagon
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1539210A4 (de) * 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp Modifizierte glp-1-rezeptoragonisten und ihrer pharmakologischen anwendungsverfahren
WO2004078195A1 (ja) 2003-03-07 2004-09-16 Ajinomoto Co., Inc. 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
EP1654004A2 (de) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthese und applikation von neuen strukturellen gut definierten verzweigten polymeren als konjugatmittel für peptide
JP2008502301A (ja) 2003-10-10 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ ペプチドの抱合
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
EP2422807A3 (de) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybridpolypeptide mit auswahlbaren Eigenschaften
AU2005231359A1 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US20090175795A1 (en) 2005-07-29 2009-07-09 Amprotein Corporation Chimeric therapeutic agents
PT1767545E (pt) * 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2163243A1 (de) 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern

Also Published As

Publication number Publication date
US20100068289A1 (en) 2010-03-18
PT2015736E (pt) 2011-05-30
EP2015736B1 (de) 2011-03-23
CN101489539A (zh) 2009-07-22
WO2007128443A2 (en) 2007-11-15
CA2649902A1 (en) 2007-11-15
ATE502628T1 (de) 2011-04-15
JP2009536166A (ja) 2009-10-08
JP5209608B2 (ja) 2013-06-12
EP2015736A2 (de) 2009-01-21
ATE444741T1 (de) 2009-10-15
WO2007128443A3 (en) 2008-05-22
US20140105991A1 (en) 2014-04-17
ES2363810T3 (es) 2011-08-17
EP1854455B1 (de) 2009-10-07
AU2007247511B2 (en) 2012-12-06
US8790705B2 (en) 2014-07-29
EP1854455A1 (de) 2007-11-14
PL2015736T3 (pl) 2011-09-30
DE602006009631D1 (de) 2009-11-19
DK2015736T3 (da) 2011-06-14
EP2174655A1 (de) 2010-04-14
AU2007247511A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
DE602007013385D1 (de) Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung
WO2010049678A3 (en) Treatment of energy utilization diseases
CR10852A (es) Compuestos biciclicos y su uso como anti-diabeticos
TW200720729A (en) Multilayer body with electrically controllable optically active systems of layers
WO2005068498A3 (en) Human therapeutic cells secreting nerve growth factor
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
WO2012138919A9 (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
DE50312016D1 (de) Herstellung uretdiongruppenhaltiger Polyisocyanate mit Cycloalkylphosphinen als Katalysatoren
JP2010525875A5 (de)
ATE540655T1 (de) Windel mit elastischer oberschicht
WO2009111317A3 (en) Endoscopic delivery of red/nir light to the substantia nigra to treat parkinson's disease
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
WO2009117631A3 (en) Methods and apparatuses for providing a sleep system having customized zoned support and zoned comfort
WO2008122441A3 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
ATE477798T1 (de) Verwendung von agomelatin zur herstellung von medikamenten zur behandlung der generalisierten angststörung
IL213617A (en) Process of microsolation of Sertoli cell, received microcapsules and their use for the prevention or cure of type 1 diabetes mellitus
DE602008000215D1 (de) Aktives Verbundanodenmaterial, Herstellungsverfahren dafür sowie Anode und Lithiumbatterie mit dem Material
WO2008061209A3 (en) G protein coupled receptors and uses thereof
WO2005101013A3 (en) Materials and methods for screening modulators of neural regneration
DE102005054091A1 (de) Schwefelvernetzte hydrierte Vinylpolybutadiene sowie deren Verwendung zur Herstellung von technischen Gummiartikeln mit guten Rückverformungsverhalten über einen breiten Temperaturbereich
ATE549400T1 (de) Polypeptid mit esterase aktivität sowie rekombinante esterase und verwendung davon
WO2010137978A3 (en) Method for manufacturing a sitting orthosis from a representation of the contact surface of the sitting orthosis, and a sitting orthosis manufactured in such a manner
WO2008091598A3 (en) CONFORMATION AND ACTIVITY OF Gβ5 COMPLEXES
WO2006123930A3 (en) Nucleic acids and polypeptides that are useful in controlling neuronal regeneration
WO2007034480A3 (en) Heparanases and splice variants thereof, ponucleotides encoding them and uses thereof